Статті в журналах з теми "Mifamurtide"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Mifamurtide".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Tacyildiz, Nurdan, Sonay incesoy Ozdemir, Emel Cabi Unal, Handan Dincaslan, Gulsan Yavuz, Fikret Asarcikli, Gulsah Tanyildiz, and Yusuf Yildiz. "Efficiency and toxicity of mifamurtid in childhood osteosarcoma." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e22010-e22010. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e22010.
Повний текст джерела&NA;. "Mifamurtide." Drugs in R & D 9, no. 2 (2008): 131–35. http://dx.doi.org/10.2165/00126839-200809020-00007.
Повний текст джерелаFrampton, James E. "Mifamurtide." Pediatric Drugs 12, no. 3 (June 2010): 141–53. http://dx.doi.org/10.2165/11204910-000000000-00000.
Повний текст джерелаNastasi, Nicoletta, Angela Subbiani, Maria Letizia Taddei, Lucia Scala, Angela Tamburini, Claudio Favre, and Maura Calvani. "Abstract 2007: Use of an anti-IL-10 antibody to improve Mifamurtide efficacy on aggressive osteosarcoma cells." Cancer Research 82, no. 12_Supplement (June 15, 2022): 2007. http://dx.doi.org/10.1158/1538-7445.am2022-2007.
Повний текст джерелаBrard, Caroline, Sophie Piperno-Neumann, Jessy Delaye, Laurence Brugières, Lisa V. Hampson, Gwénaël Le Teuff, Marie-Cécile Le Deley, and Nathalie Gaspar. "Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma." BMJ Open 9, no. 5 (May 2019): e025877. http://dx.doi.org/10.1136/bmjopen-2018-025877.
Повний текст джерела&NA;. "Mifamurtide boosts chemo efficacy in osteosarcoma." Inpharma Weekly &NA;, no. 1626 (February 2008): 7. http://dx.doi.org/10.2165/00128413-200816260-00016.
Повний текст джерела&NA;. "Mifamurtide receives positive opinion in Europe." Inpharma Weekly &NA;, no. 1666 (November 2008): 22. http://dx.doi.org/10.2165/00128413-200816660-00061.
Повний текст джерелаAnderson, P. M., M. Tomaras, and K. McConnell. "Mifamurtide in osteosarcoma - A practical review." Drugs of Today 46, no. 5 (2010): 327. http://dx.doi.org/10.1358/dot.2010.46.5.1500076.
Повний текст джерелаAndo, Kosei, Kanji Mori, Nedège Corradini, Françoise Redini, and Dominique Heymann. "Mifamurtide for the treatment of nonmetastatic osteosarcoma." Expert Opinion on Pharmacotherapy 12, no. 2 (January 13, 2011): 285–92. http://dx.doi.org/10.1517/14656566.2011.543129.
Повний текст джерелаMeyers, Paul A. "Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma." Expert Review of Anticancer Therapy 9, no. 8 (August 2009): 1035–49. http://dx.doi.org/10.1586/era.09.69.
Повний текст джерелаTacyildiz, Nurdan, Sonay Incesoy Ozdemir, Emel Unal, Melda Berber, Handan Dincaslan, and Gulsan Yavuz. "The Efficiency and Toxicity of Mifamurtide in Childhood Osteosarcoma." Journal of Pediatric Hematology/Oncology 40, no. 6 (August 2018): e373-e376. http://dx.doi.org/10.1097/mph.0000000000001236.
Повний текст джерелаŞimşek, Meral, Erman Ataş, Emin Ümit Bağrıaçık, Armağan Günal, and Bülent Ünay. "Type 4 hypersensitivity development in a case due to mifamurtide." Turkish Journal of Pediatrics 62, no. 4 (2020): 694. http://dx.doi.org/10.24953/turkjped.2020.04.025.
Повний текст джерелаLi, Yuexian, Mihaela Plesescu, and Shimoga R. Prakash. "Synthesis of isotopically labeled versions ofL-MTP-PE (mifamurtide) and MDP." Journal of Labelled Compounds and Radiopharmaceuticals 56, no. 9-10 (July 2013): 475–79. http://dx.doi.org/10.1002/jlcr.3078.
Повний текст джерелаVenkatakrishnan, K., P. Meyers, D. R. Mould, B. Green, T. W. Synold, C. Oliva, and P. Anderson. "9428 POSTER Pharmacokinetics and Pharmacodynamics of Liposomal Mifamurtide in Patients With Osteosarcoma." European Journal of Cancer 47 (September 2011): S671. http://dx.doi.org/10.1016/s0959-8049(11)72572-2.
Повний текст джерелаJimmy, Rincy, Cindy Stern, Karolina Lisy, and Sarahlouise White. "Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma." JBI Database of Systematic Reviews and Implementation Reports 15, no. 8 (August 2017): 2113–52. http://dx.doi.org/10.11124/jbisrir-2016-003105.
Повний текст джерелаPalmerini, Emanuela, Catalina Marquez, Cristina Meazza, Angela Tamburini, Gianni Bisogno, Francisco José Bautista Sirvent, Virginia Ferraresi, et al. "ABCB1/P-glycoprotein (Pgp) expression as stratification factor for treatment of patients with non-metastaticextremity high-grade osteosarcoma: A merged analysis of an Italian (ISG) and a Spanish (GEIS) sarcoma groups' multicentric prospective trials." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 11527. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.11527.
Повний текст джерела&NA;. "Mifamurtide* [L-MTP-PE] has displayed encouraging activity in patients with advanced osteosarcoma." Inpharma Weekly &NA;, no. 1639 (May 2008): 7. http://dx.doi.org/10.2165/00128413-200816390-00017.
Повний текст джерелаPunzo, Francesca, Giulia Bellini, Chiara Tortora, Daniela Di Pinto, Maura Argenziano, Elvira Pota, Alessandra Di Paola, Martina Di Martino, and Francesca Rossi. "Mifamurtide and TAM-like macrophages: effect on proliferation, migration and differentiation of osteosarcoma cells." Oncotarget 11, no. 7 (February 18, 2020): 687–98. http://dx.doi.org/10.18632/oncotarget.27479.
Повний текст джерелаBekçioğlu, Ömer, Safiye Aktas, Melek Aydın, and Nur Olgun. "The Effect of Ifosfamide and Mifamurtide Loaded Cement on The Viability of Osteosarcoma Cells." Turkish Journal of Hip Surgery 1, no. 3 (2021): 90–95. http://dx.doi.org/10.5505/tjhs.2021.76486.
Повний текст джерелаJohal, Sukhvinder, Stephen Ralston, and Christopher Knight. "Mifamurtide for High-Grade, Resectable, Nonmetastatic Osteosarcoma Following Surgical Resection: A Cost-Effectiveness Analysis." Value in Health 16, no. 8 (December 2013): 1123–32. http://dx.doi.org/10.1016/j.jval.2013.08.2294.
Повний текст джерелаBrosa, M., del Muro X. García, J. Mora, A. Villacampa, T. Pozo, C. Adán, M. Grande, E. García, and L. Cubells. "Economic Considerations On the Use of Mifamurtide In the Treatment of Osteosarcoma In Spain." Value in Health 17, no. 7 (November 2014): A526—A527. http://dx.doi.org/10.1016/j.jval.2014.08.1662.
Повний текст джерелаMonge, Claire, Camille Ayad, Anne-Lise Paris, Renaud Rovera, Evelyne Colomb, and Bernard Verrier. "Mucosal Adjuvants Delivered by a Mucoadhesive Patch for Sublingual Administration of Subunit Vaccines." International Journal of Molecular Sciences 23, no. 21 (November 3, 2022): 13440. http://dx.doi.org/10.3390/ijms232113440.
Повний текст джерелаMúdry, Peter, Michal Kýr, Ondřej Rohleder, Michal Mahdal, Iva Staniczková Zambo, Marta Ježová, Tomáš Tomáš, and Jaroslav Štěrba. "Improved osteosarcoma survival with addition of mifamurtide to conventional chemotherapy – Observational prospective single institution analysis." Journal of Bone Oncology 28 (June 2021): 100362. http://dx.doi.org/10.1016/j.jbo.2021.100362.
Повний текст джерелаVenkatakrishnan, Karthik, Yi Liu, Dennis Noe, Jaime Mertz, Michael Bargfrede, Thomas Marbury, Kambiz Farbakhsh, Cristina Oliva, and Ashley Milton. "Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate renal impairment." British Journal of Clinical Pharmacology 77, no. 6 (May 22, 2014): 986–97. http://dx.doi.org/10.1111/bcp.12260.
Повний текст джерелаVenkatakrishnan, Karthik, Yi Liu, Dennis Noe, Jaime Mertz, Michael Bargfrede, Thomas Marbury, Kambiz Farbakhsh, Cristina Oliva, and Ashley Milton. "Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment." British Journal of Clinical Pharmacology 77, no. 6 (May 22, 2014): 998–1010. http://dx.doi.org/10.1111/bcp.12261.
Повний текст джерела&NA;. "Additional data is required by European regulatory authorities considering IDM Pharma's marketing authorisation application for mifamurtide." Inpharma Weekly &NA;, no. 1646 (July 2008): 19. http://dx.doi.org/10.2165/00128413-200816460-00055.
Повний текст джерелаVenkatakrishnan, Karthik, William G. Kramer, Timothy W. Synold, Daniel B. Goodman, Evin Sides, and Cristina Oliva. "A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers." European Journal of Clinical Pharmacology 68, no. 10 (March 30, 2012): 1347–55. http://dx.doi.org/10.1007/s00228-012-1262-1.
Повний текст джерелаJimmy, Rincy, Sarahlouise White, and Karolina Lisy. "Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma: A systematic review protocol." JBI Database of Systematic Reviews and Implementation Reports 12, no. 11 (December 11, 2014): 61. http://dx.doi.org/10.11124/jbisrir-2014-1774.
Повний текст джерелаAnderson, P. M., P. Meyers, E. Kleinerman, K. Venkatakrishnan, D. P. Hughes, C. Herzog, W. Huh, et al. "Mifamurtide in metastatic and recurrent osteosarcoma: A patient access study with pharmacokinetic, pharmacodynamic, and safety assessments." Pediatric Blood & Cancer 61, no. 2 (August 31, 2013): 238–44. http://dx.doi.org/10.1002/pbc.24686.
Повний текст джерелаBrosa, Max, Xavier García del Muro, Jaume Mora, Alba Villacampa, Tamara Pozo-Rubio, Laia Cubells, and Carmen Montoto. "Orphan drugs revisited: cost–effectiveness analysis of the addition of mifamurtide to the conventional treatment of osteosarcoma." Expert Review of Pharmacoeconomics & Outcomes Research 15, no. 2 (October 29, 2014): 331–40. http://dx.doi.org/10.1586/14737167.2015.972378.
Повний текст джерелаLewis, I. J., C. Oliva, and Y. Liu. "Observational, Noninterventional Surveillance Study of Patients with High-Grade Osteosarcoma who are Candidates for Liposomal Mifamurtide Treatment." Annals of Oncology 23 (September 2012): ix490—ix491. http://dx.doi.org/10.1016/s0923-7534(20)34066-7.
Повний текст джерелаSong, Hyun Jin, Eui-Kyung Lee, Jun Ah Lee, Hye-Lin Kim, and Kyoung Won Jang. "The addition of mifamurtide to chemotherapy improves lifetime effectiveness in children with osteosarcoma: a Markov model analysis." Tumor Biology 35, no. 9 (May 30, 2014): 8771–79. http://dx.doi.org/10.1007/s13277-014-2139-y.
Повний текст джерелаBerisa, S., E. Lacalle, ME Carrasco, F. Marcotegui, S. Martínez, M. Gutiérrez, M. Castresana, M. Elviro, and E. Pellejero. "DGI-034 Evaluation of the Efficacy and Safety of Mifamurtide in Osteogenic Sarcoma Treatment in Paediatric Patients." European Journal of Hospital Pharmacy 20, Suppl 1 (March 2013): A107.2—A108. http://dx.doi.org/10.1136/ejhpharm-2013-000276.300.
Повний текст джерелаSong, Hyun Jin, Jun Ah Lee, Euna Han, and Eui-Kyung Lee. "Lifetime effectiveness of mifamurtide addition to chemotherapy in nonmetastatic and metastatic osteosarcoma: a Markov process model analysis." Tumor Biology 36, no. 9 (April 3, 2015): 6773–79. http://dx.doi.org/10.1007/s13277-015-3405-3.
Повний текст джерелаVargas-Romero, J. A., A. Figueroa-Rodriguez, J. Chiu-Ugalde, R. Sánchez-Kobashi, J. G. Gay-Molina, and J. C. López-Alvarenga. "Cost-Effectiveness and Cost-Utility Analysis of Mifamurtide Plus Combination Chemotherapy in Pediatric Patients with Osteosarcoma After Resection Surgery." Value in Health 16, no. 7 (November 2013): A686. http://dx.doi.org/10.1016/j.jval.2013.08.2035.
Повний текст джерелаAnderson, P., P. Meyers, E. Kleinerman, C. Oliva, and Y. Liu. "Mifamurtide (L-MTP-PE) for Metastatic and Recurrent Osteosarcoma (OS): Survival and Safety Profile from a Patient Access Study." Annals of Oncology 23 (September 2012): ix488. http://dx.doi.org/10.1016/s0923-7534(20)34055-2.
Повний текст джерелаVenkatakrishnan, K., Y. Liu, D. Noe, J. Mertz, M. Mockler, T. Marbury, K. Farbakhsh, C. Oliva, and A. Milton. "593 Pharmacokinetics (PK) and Pharmacodynamics (PD) of Liposomal Mifamurtide (L-MTP-PE) in Adult Volunteers with Mild and Moderate Hepatic Impairment (HI)." European Journal of Cancer 48 (November 2012): 182. http://dx.doi.org/10.1016/s0959-8049(12)72390-0.
Повний текст джерелаMartinez Beltrán, Leila, Daniel Ozaeta Eidelman, and Natalia Lucía González Suárez. "Caracterización de los niños con osteosarcoma no metastásico quienes recibieron tratamiento con mifamurtida en dos instituciones de Bogotá (Colombia) entre 2014 y 2017." Universitas Médica 60, no. 4 (September 30, 2019): 1–8. http://dx.doi.org/10.11144/javeriana.umed60-4.oste.
Повний текст джерелаVenkatakrishnan, K., Y. Liu, D. Noe, J. Mertz, C. Oliva, and A. Milton. "582 Total and Non-liposome Associated (free) Muramyl Tripeptide-Phosphatidyl Ethanolamine (MTP-PE) Pharmacokinetics (PK) Following Intravenous (IV) Infusion of Liposomal Mifamurtide to Healthy Adults." European Journal of Cancer 48 (November 2012): 178. http://dx.doi.org/10.1016/s0959-8049(12)72379-1.
Повний текст джерелаEmmerich, I. U. "Neue Arzneimittel für Kleintiere 2010." Tierärztliche Praxis Ausgabe K: Kleintiere / Heimtiere 39, no. 06 (2011): 429–35. http://dx.doi.org/10.1055/s-0038-1623608.
Повний текст джерела"Mifamurtide." Reactions Weekly 1845, no. 1 (March 2021): 250. http://dx.doi.org/10.1007/s40278-021-92133-1.
Повний текст джерела"Mifamurtide." Reactions Weekly 1717, no. 1 (September 2018): 193. http://dx.doi.org/10.1007/s40278-018-51263-z.
Повний текст джерела"Mifamurtide." Reactions Weekly 1828, no. 1 (October 2020): 325. http://dx.doi.org/10.1007/s40278-020-85401-y.
Повний текст джерела"Mifamurtide." Reactions Weekly 1665, no. 1 (August 2017): 189. http://dx.doi.org/10.1007/s40278-017-34758-7.
Повний текст джерела"Mifamurtide." Reactions Weekly 1930, no. 1 (October 29, 2022): 352. http://dx.doi.org/10.1007/s40278-022-26615-4.
Повний текст джерелаReview Editor, Business. "Junovan (mifamurtide)." PharmaDeals Review 2007, no. 80 (February 1, 2007). http://dx.doi.org/10.3833/pdr.v2007i80.384.
Повний текст джерела"Not so NICE for mifamurtide." PharmacoEconomics & Outcomes News 608, no. 1 (July 2010): 3. http://dx.doi.org/10.2165/00151234-201006080-00007.
Повний текст джерела"Molecule of the month. Mifamurtide." Drug News & Perspectives 23, no. 3 (2010): 199. http://dx.doi.org/10.1358/dnp.2010.23.3.1492241.
Повний текст джерела"Draft NICE guidance does not recommend mifamurtide." PharmacoEconomics & Outcomes News 614, no. 1 (October 2010): 9. http://dx.doi.org/10.2165/00151234-201006140-00020.
Повний текст джерела"NICE news for mifamurtide, tocilizumab and ticagrelor." PharmacoEconomics & Outcomes News 641, no. 1 (November 2011): 10. http://dx.doi.org/10.2165/00151234-201106410-00030.
Повний текст джерела